ITherX Repurposes Kemia Drug

Xconomy San Diego — 

San Diego’s ITherX Pharmaceuticals has begun enrolling liver transplant patients in an early stage hepatitis C trial that seeks to repurpose a drug that was initially under development for treating inflammation. ITherX, with backing from Easton Capital and others, acquired the experimental compound from San Diego-based Kemia in 2009 for $75,000, according to VentureWire. In a proof-of-concept trial that began earlier this month, ITherX says it is testing whether the compound can help prevent the hepatitis C virus from infecting the transplanted liver. Kemia, which discovered the molecule, halted development after the drug failed a mid-stage trial for rheumatoid arthritis.